rare blood coagulation disease

Economy China bans export of Korean goods containing its rare earth metals to US

The Chinese government has warned South Korean companies of retributions for exporting any product containing its critical metals to US military con...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Bio & Pharma ABL Bio lands $2.8 billion license-out deal with GSK

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-bas...

Korean Investors Samsung to invest $10 million in US-based C2N Diagnostics

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Batteries SK Ecoplant, BMW team up for battery recycling

SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, partnered with German luxury carmaker BMW to...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma GC Biopharma acquires ABO Holding for $96 mn

South Korea’s GC Biopharma Corp. said on Thursday it acquired the US-based medical-grade source blood plasma company ABO Holding Inc. The...

Bio & Pharma Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Bio & Pharma Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Bio & Pharma Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Korean startups Near Brain gives hope to millions of stroke patients worldwide

Strokes are the second leading cause of death and the third leading cause of disabilities globally, according to the World Health Organization.To fi...

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Bio & Pharma Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Bio & Pharma Celltrion gets approval of Steqeyma in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

Bio & Pharma GC Biopharma sells HK subsidiary to CR Pharm Group for $254 mn

South Korea’s GC Biopharma Corp. announced on Wednesday that it signed a share purchase agreement (SPA) to sell all its shares in its Hong Kon...

North Korea A North Korean Diplomat Managed a Rare Defection: A Flight Out of Cuba

SEOUL—A North Korean diplomat posted in Cuba defected to South Korea with his family late last year, officials said this week, a rare esc...

Bio & Pharma GC Biopharma exports Alyglo to US

South Korea’s major pharmaceutical company GC Biopharma Corp. announced on Monday that it shipped the initial volume of Alygro, its immunoglob...

Electric vehicles Korea Eximbank to provide $150 mn PF to Australia

The Export-Import Bank of Korea (Eximbank) announced on Tuesday that it will provide $150 million in project financing (PF) for developing a rare ea...

Electric vehicles Hyundai Motor, Kia to develop alternative to rare earth materials

Hyundai Motor Co. and Kia Corp. have partnered with South Korea's universities to secure materials for vehicle electrification components.Hyundai Mo...

Business & Politics SoftBank to buy part of Naver's Line stake by July: CEO Miyakawa

TOKYO – SoftBank Corp., which runs LY Corp., the operator of the popular mobile messenger app Line in Japan, said on Thursday it is in talks w...

Bio & Pharma Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

Bio & Pharma Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

Bio & Pharma Celltrion releases Remsima SC in Denmark

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Bio & Pharma Bio startup ArtBlood attracts $4.8 mn investment

South Korean bio startup ArtBlood, specializing in blood production for transfusion, announced on Tuesday that it successfully secured an investment...

Bio & Pharma Samsung begins new drug development for rare diseases

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

Bio & Pharma Reversing age possible in a decade: Harvard Prof. David Sinclair

Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...

Bio & Pharma Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

Bio & Pharma Celltrion ships initial supply of Zymfentra to US

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Artificial intelligence Kakao Brain releases medical GenAI tech for free

Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...